ALLIANCE UPDATE

Companies Agreement

Ares-Serono & Organon	In the District Court of The Hague, Ares-Serono has been denied a summary injunction against Organon for Organon's alleged infringement of Ares-Serono's European patent (No. 211,894) for recombinant follicle stimulating hormone.
Cantab & Baxter	The two will expand their 1991 collaboration involving LM-CD45, a monoclonal antibody designed to prevent acute rejection in organ transplants. Baxter will, in addition to its already exclusive marketing rights in North America and Europe, gain exclusive worldwide manufacturing rights and exclusive marketing rights in Japan and Pacific Rim nations.
Cantab & Cancer Research	The two will develop a novel immunotherapeutic—one involving human-papilloma-virus proteins—to treat genital warts and prevent their recurrence.
Cephalon & Kyowa Hakko Kogyo	The agreement involves Japanese development and marketing of Myotrophin, a recombinant form of human insulin-like growth factor-1, which is currently in clinical trials for neurological disorders. Kyowa will fund development, conduct clinical trials, and seek registration to market the drug.

Collaborative
Abbott The two will use Collaborative's experience in large-scale DNA manipulation, sequencing, and cloning to focus on tuberculosis, manic depression, drug-screening methodologies, and cancers.

Genentech
& Wellcome
Foundation Genentech, after five years of litigation, has been awarded a permanent injunction against Wellcome, preventing Wellcome from marketing tissue plasminogen activator (t-PA) in the U.S. until 2005, which is when Genentech's t-PA patents expire.

Gensia
& Marion
Merrell Dow Gensia will retain exclusive marketing rights to Arasine, a drug used in coronary-artery-bypass surgery. Under the agreement, which expands a 1990 collaboration to develop orally active adenosine-regulating agents for cardiovascular and cerebrovascular disease, Marion will have the option to copromote this and other future compounds.

Genta
Proctor & Gamble A collaboration to develop Genta's Anticodon oligonucleotides for certain infectious diseases has been extended through September 1995.

Hemosol
& Netherlands
Red Cross The two will collaborate on the development of cross-linked hemoglobin solutions. They will grant each other nonexclusive rights to each other's technology for research purposes, and they will assist each other through the maze of regulatory, clinical, and patent strategies.

Hoffmann-La Roche
& Perkin-Elmer
& Boehringer To accelerate the development of PCR applications, Roche and Perkin-Elmer will grant a license to Boehringer Mannheim to manufacture and sell Taq DNA polymerase and other thermostable enzymes and products for use in PCR.

ImClone Systems
& Erbamont ImClone has regained worldwide rights to interleukin-6 mutein (IL-6m) from its partner, Erbamont. IL-6m is a cytokine that generates mature platelets from precursor blood cells.

MedImmune
& American
Cyanamid The two will develop and market three generations of products for respiratory syncytial virus, including MedImmune's Respivir, and will copromote Zosyn, a Cyanamid anti-infective already available overseas but awaiting U.S. marketing approval. Cyanamid will also pay up to \$30 million to MedImmune.

Organogenesis
& Biomet Organogenesis has teamed with Biomet to develop orthopedic implants using Organogenesis' dense fibrillar collagen. Biomet will exclusively market any resulting compounds, while Organogenesis will manufacture the compounds. Organogenesis has also discontinued its alliance with Eli Lilly, because Lilly claimed that certain milestones in the development of Graftartery, a small diameter arterial replacement, were not met.

Prizm
& Farmitalia Carlo Prizm has obtained an exclusive sublicense from Farmitalia to technology for making and using fibroblast growth factor conjugates covered in five patent filings.

Quidel
& Clonatec Quidel will acquire the home-fertility-testing business of Clonatec, which currently is second in the \$20-million French home-testing market.

Regeneron
& Glaxo The two will collaborate on low-molecular-weight, orally active compounds for neurological disorders. Glaxo will conduct clinical trials and manufacture future products. Glaxo will also pay \$10 million for 500,000 unregistered shares of Regeneron common stock.

SciClone
& Sclavo SciClone has contracted Sclavo to provide, initially, 1.5 million units per year of Zadaxin thymosin alpha 1, which treats chronic hepatitis B. The compound is currently in or near clinical trials in Taiwan, Singapore, Japan, Mexico, and several Latin American countries.

Sepracor
& Biopass The two will market chromatography systems for production-scale purification of biomolecules. Sepracor will exclusively market in North America a line of chromatography systems manufactured by Biopass, incorporating them into its own ProSys family of bioprocessing systems. Biopass will also use Sepracor's HyperDiffusion technology to produce purification systems.

—Mark Goodstein